An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2

被引：0

作者：

Lee, J-Y ^{[1
,2
]}

Makker, V. ^{[3
]}

Oaknin, A. ^{[4
]}

Oh, D-Y ^{[5
]}

Anoka, C. ^{[6
]}

Jung, L. ^{[6
]}

Simoes, J. ^{[7
]}

Puvvada, S. D. ^{[8
]}

Meric-Bernstam, F. ^{[9
]}

机构：

[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Obstet & Gynecol, Seoul, South Korea

[2] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea

[3] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, New York, NY USA

[4] Hosp Univ Vall dHebron, Gynaecol Canc Programme, Barcelona, Spain

[5] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[6] AstraZeneca, Oncol R&D, Gaithersburg, MD USA

[7] AstraZeneca, Oncol R&D, Cambridge, CA USA

[8] AstraZeneca, Oncol R&D, South San Francisco, CA USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

400TiP

引用

页码：S1553 / S1553

页数：1